ArticlebioRxiv : the preprint server for biology2025
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer.
Jessica Armand et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.